Results 91 to 100 of about 8,268,208 (290)
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu +4 more
wiley +1 more source
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. [PDF]
BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by ...
Younus, A +42 more
core +1 more source
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Yueshuo Li +9 more
wiley +1 more source
This study identifies MZF1 as a core regulator of colon cancer via SnoN‐mediated TGF‐β suppression, proposes 10Panx Acetate as a targeted inhibitor, and validates MZF1/SnoN as prognostic markers for aggressive disease. ABSTRACT Colon cancer progression is associated with transcriptional and signaling abnormalities.
Siqi Sheng +9 more
wiley +1 more source
Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening [PDF]
This study aimed to investigate the optimal screening interval of a prostate specific antigen (PSA) screening program for men aged 40–70 with a baseline PSA 10 ng/mL, or 4–10 ng/mL (gray area) and f/t PSA
Yu Chen, Gansheng Xie, Gang Li, Yu Li
doaj +1 more source
Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang +11 more
wiley +1 more source
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu +10 more
wiley +1 more source
Yeasin Ahamed,1,2 Lichao Wu,1 Shantanu Baral,1 Ashab Uddin Al-Raiyan,1 Weigui Sun1,2 1Department of Urology Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Clinical Medical College ...
Ahamed Y +4 more
doaj
Purpose: Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors.
Loeb, S +16 more
core +1 more source

